Abstract 461P
Background
Lung cancer is the leading cause of cancer deaths worldwide including in India. Around 80% of these are Non Small Cell Lung Cancers (NSCLC) detected in advanced stages where surgical resection is not an option and locally advanced stage patients are treated with concurrent chemoradiotherapy.
Methods
A total of 90 patients of NSCLC Stages IIIA and IIIB participated in the study conducted over the last eighteen months. They were randomized and distributed between two arms in 1:1 ratio. Their pre-treatment Pulmonary Function Tests were recorded. Participants in Arm A underwent 30 minutes of yoga session daily besides standard fractionation radiotherapy with concurrent weekly chemotherapy. Participants in Arm B received the same schedule of concurrent chemoradiotherapy but without the daily yoga session. Their post-treatment Pulmonary Function Tests were recorded at six weeks post completion of chemoradiotherapy and compared with pre-treatment values.
Results
21 participants in Arm A recorded positive changes in their FEV1 values, compared to just 3 patients in Arm B (p=0.0002), suggesting daily yoga sessions during treatment can actually help in improvement of lung function among locally advanced NSCLC patients.
Conclusions
Further multi-institutional studies with more participants should be encouraged and yoga be more maistreamed and formally incoporated into standard therapeutic regimens for the management of locally advanced non small cell lung cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract